Precise RNA targeting with CRISPR-Cas13d.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39934271.
- Also identified by DOI 10.1038/s41587-025-02558-3.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The possibility of collateral RNA degradation poses a concern for transcriptome perturbations and therapeutic applications using CRISPR-Cas13. We show that collateral activity only occurs with high RfxCas13d expression. Using low-copy RfxCas13d in transcriptome-scale and combinatorial pooled screens, we achieve high on-target knockdown without extensive collateral activity. Furthermore, analysis of a high-fidelity Cas13 variant suggests that its reduced collateral activity may be due to overall diminished nuclease capability.
Medical subject headings
- CRISPR-Cas Systems
- RNA
- Gene Editing